Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

HUM

Why Are People Selling Their HUM Shares?

Humana stock is trading -16.88% below its average target price of $298.09 after dropping -4.8% during today's afternoon session. Analysts are giving the Large-Cap Medical Specialities company an average rating of buy and target prices ranging from $250.0 to $353.0 per share.

Humana's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 3.8%. The stock's short ratio is 2.42. The company's insiders own 0.21% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.

Another number to watch is the company's rate of institutional share ownership, which now stands at 96.0%. In conclusion, we believe there is mixed market sentiment regarding Humana.

Institutions Invested in Humana

Date Reported Holder Percentage Shares Value
2025-06-30 Vanguard Group Inc 12% 14,199,096 $3,518,110,076
2025-06-30 Dodge & Cox Inc 9% 11,352,920 $2,812,913,036
2025-06-30 Blackrock Inc. 9% 10,245,750 $2,538,589,521
2025-06-30 State Street Corporation 4% 5,377,390 $1,332,355,943
2025-06-30 Pzena Investment Management LLC 3% 4,076,667 $1,010,075,800
2025-06-30 Eagle Capital Management LLC 3% 3,949,474 $978,561,189
2025-06-30 FMR, LLC 3% 3,146,946 $779,718,823
2025-06-30 Geode Capital Management, LLC 3% 3,130,829 $775,725,514
2025-06-30 JPMORGAN CHASE & CO 3% 3,013,306 $746,606,840
2025-06-30 Sessa Capital IM, L.P. 2% 2,123,965 $526,254,817
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS